Caxton Associates (New York)’s CME Group CME Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | $15.4M | Hold |
66,293
| – | – | 0.48% | 26 |
|
|
2024
Q3 | $14.6M | Sell |
66,293
-3,863
| -6% | -$799K | 0.55% | 19 |
|
|
2024
Q2 | $13.8M | Buy |
70,156
+10,156
| +17% | +$2.1M | 0.47% | 32 |
|
|
2024
Q1 | $12.9M | Sell |
60,000
-4,845
| -7% | -$1.02M | 0.72% | 17 |
|
|
2023
Q4 | $13.7M | Buy |
64,845
+1,035
| +2% | +$221K | 0.7% | 37 |
|
|
2023
Q3 | $12.8M | Buy |
63,810
+2,528
| +4% | +$503K | 1.76% | 9 |
|
|
2023
Q2 | $11.4M | Buy |
61,282
+1,282
| +2% | +$237K | 1.68% | 9 |
|
|
2023
Q1 | $11.5M | Sell |
60,000
-14,805
| -20% | -$2.68M | 1.73% | 8 |
|
|
2022
Q4 | $12.6M | Buy |
74,805
+7,573
| +11% | +$1.32M | 0.84% | 11 |
|
|
2022
Q3 | $11.9M | Buy |
67,232
+7,232
| +12% | +$1.43M | 1.59% | 11 |
|
|
2022
Q2 | $12.3M | Hold |
60,000
| – | – | 1.19% | 11 |
|
|
2022
Q1 | $14.3M | Sell |
60,000
-3,934
| -6% | -$924K | 1.16% | 15 |
|
|
2021
Q4 | $14.6M | Buy |
63,934
+3,934
| +7% | +$866K | 1.49% | 15 |
|
|
2021
Q3 | $11.6M | Sell |
60,000
-8,037
| -12% | -$1.63M | 1.28% | 14 |
|
|
2021
Q2 | $14.5M | Buy |
68,037
+8,037
| +13% | +$1.7M | 1.59% | 12 |
|
|
2021
Q1 | $12.3M | Buy |
+60,000
| New | +$11.8M | 1.11% | 15 |
|
|
2020
Q4 | – | Sell |
-4,378
| Closed | -$732K | – | 168 |
|
|
2020
Q3 | $732K | Buy |
4,378
+1,077
| +33% | +$181K | 0.08% | 73 |
|
|
2020
Q2 | $537K | Sell |
3,301
-4,076
| -55% | -$731K | 0.05% | 124 |
|
|
2020
Q1 | $1.28M | Buy |
+7,377
| New | +$1.47M | 0.23% | 39 |
|
|
2019
Q4 | – | Sell |
-11,301
| Closed | -$2.39M | – | 414 |
|
|
2019
Q3 | $2.39M | Sell |
11,301
-8,699
| -43% | -$1.82M | 0.47% | 21 |
|
|
2019
Q2 | $3.88M | Buy |
+20,000
| New | +$3.69M | 0.47% | 40 |
|
|
2019
Q1 | – | Sell |
-2,233
| Closed | -$420K | – | 391 |
|
|
2018
Q4 | $420K | Buy |
+2,233
| New | +$412K | 0.07% | 132 |
|
|
2018
Q3 | – | Sell |
-40,881
| Closed | -$6.7M | – | 422 |
|
|
2018
Q2 | $6.7M | Buy |
40,881
+32,540
| +390% | +$5.31M | 0.34% | 62 |
|
|
2018
Q1 | $1.35M | Buy |
+8,341
| New | +$1.33M | 0.07% | 159 |
|
|
2017
Q3 | – | Sell |
-4,300
| Closed | -$539K | – | 507 |
|
|
2017
Q2 | $539K | Buy |
+4,300
| New | +$514K | 0.02% | 314 |
|
Other funds holding CME
Caxton Associates (New York)'s CME Position: Q4 2024 in Review
Caxton Associates (New York) held its CME Group (CME) position steady in Q4 2024 at 66,293 shares worth $15.4M. The position accounts for 0.48% of the portfolio, ranked #26.
Caxton Associates (New York) first reported a position in CME in Q2 2017 and has held it in 25 quarters since. 1,500 funds tracked by Wall St. Rank hold CME as of Q4 2024.
- Caxton Associates (New York) held 66,293 shares of CME Group worth $15.4M as of Q4 2024.
- Caxton Associates (New York) left its CME Group share count unchanged in Q4 2024.
- CME Group made up 0.48% of Caxton Associates (New York)'s portfolio in Q4 2024, its #26 holding.
- Caxton Associates (New York) first reported a position in CME Group in Q2 2017 and has held it in 25 quarters since.
- 1,500 funds tracked by Wall St. Rank held CME Group as of Q4 2024.
Based on Caxton Associates (New York)'s 13F filing for Q4 2024, filed 14 Feb 2025.